Remicade
FDA advisory committee recommends approval of Remicade biosimilar
February 10, 2016Research and Development, Sales and Marketing FDA, Pfizer, Remicade, biosimilar, celltrion
An FDA advisory panel yesterday voted overwhelmingly in favour of approving CT-P13- Celltrion’s biosimilar version of Johnson&Johnson’s blockbuster arthritis drug …
FDA set to approve Remicade biosimilar
February 9, 2016Manufacturing and Production, Research and Development, Sales and Marketing Remicade, biosimilars, remsima
An FDA committee has had some positive words for Celltrion’s biosimilar candidate to Janssen/MSD’s Remicade (infliximab), concluding that the copycat biologic …
Merck sales fall in Q1 despite new product lifts
April 29, 2015Sales and Marketing Merck, Q1, Remicade
Merck’s sales were down in the first quarter of 2015 thanks to its consumer care divestment and increasing competition for …
Napp launches biosimilar in UK
February 25, 2015Research and Development, Sales and Marketing Hospira, Napp, Remicade, anti-TNF biologic, biosimilar, infliximab, remsima
Napp Pharmaceuticals has launched its own biosimilar version of an anti-TNF biologic in Europe paving the way for patient access …
Hospira launches biosimilar monoclonal antibody
February 16, 2015Research and Development, Sales and Marketing MSD, Merck, Remicade, biosimilar. hospira, inflectra, infliximab
Hospira has won the race to become the first company to launch a biosimilar version of an anti-TNF biologic, after …
Olysio and Xarelto boost J&J’s Q4
January 21, 2015Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four
Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …
Ranbaxy launches J&J biosimilar in India
December 5, 2014Manufacturing and Production, Sales and Marketing CHMP, FDA, India, J&J, JJ, Ranbaxy, Remicade, nlem, nppa
Ranbaxy has launched the first biosimilar of Johnson & Johnson’s Remicade (infliximab) in India, marking the firm’s entry into monoclonal …
J&J profits up amid drug gains
January 23, 2014Sales and Marketing FDA, J&J, JJ, Remicade, Zytiga, olysio, q4
Johnson & Johnson’s sales in the fourth quarter of 2013 rose 4.5% compared to the same period in the previous …
Hospira’s Inflectra approved in Europe
September 10, 2013Research and Development, Sales and Marketing Hospira, Janssen, Remicade, biosimilars, inflectra
Hospira has been the first firm to meet the European Commission’s approval for a biosimilar monoclonal antibody therapy with its …
Remicade copies set for European entry
July 1, 2013Sales and Marketing CHMP, Hospira, Janssen, Remicade, arthritis, biosimilar
Janssen’s Remicade could soon come under generic pressure after a landmark recommendation by the CHMP. South Korean biotech Celltrion and …
J&J and Merck reach compromise on arthritis drug rights
April 19, 2011Sales and Marketing Johnson & Johnson, Merck & Co, Remicade, Simponi
Johnson & Johnson and Merck & Co have agreed to split the regional rights to arthritis drugs Remicade and Simponi …
Abbott wins $1.7bn Humira case
February 24, 2011Sales and Marketing Abbott, Abbott Laboratories, Centocor, Johnson and Johnson, Remicade, Simponi, TNF, golimumab, infliximab, rheumatoid arthritis
Abbott has been saved from paying Johnson & Johnson $1.7 billion after a US appeals court quashed a patent dispute …
J&J posts negative growth as pharma sales stall
January 26, 2011Sales and Marketing 2010 pharma results, J&J, JJ, Johnson and Johnson, Remicade, Risperdal Consta
Falling fourth quarter sales of Risperdal Consta and Remicade capped a year to forget for Johnson and Johnson. The company’s …
J&J and Merck heading for showdown over drug rights
September 8, 2010Sales and Marketing Johnson & Johnson, Merck, Remicade
Johnson & Johnson’s disagreement with Merck over rights to two arthritis drugs is set to come to a head in …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
